James C.  Clemmer net worth and biography

James Clemmer Biography and Net Worth

President and Chief Executive Officer Jim Clemmer joined AngioDynamics in April 2016, bringing more than 25 years of leadership within the healthcare industry and a proven track record of success.

Prior to AngioDynamics, Clemmer served as president of the $1.8 billion medical supplies segment at Covidien plc., where he directed strategic and day-to-day operations for global business divisions that collectively manufactured 23 different product categories. In addition, he managed global manufacturing, research and development, operational excellence, business development and all other functions associated with the medical supplies business. Prior to his role at Covidien, Clemmer served as group president at Kendall Healthcare, where he managed the US business across five divisions and built the strategic plan for the Medical Supplies segment before it was spun off from Tyco. Clemmer began his career at Sage Products, Inc.

Clemmer currently serves on the Board of Directors for AngioDynamics and Lantheus Medical Imaging. Clemmer is a graduate of the Massachusetts College of Liberal Arts. 

What is James C. Clemmer's net worth?

The estimated net worth of James C. Clemmer is at least $2.64 million as of October 10th, 2022. Mr. Clemmer owns 450,407 shares of AngioDynamics stock worth more than $2,643,889 as of March 28th. This net worth approximation does not reflect any other assets that Mr. Clemmer may own. Additionally, Mr. Clemmer receives a salary of $982,920.00 as CEO at AngioDynamics. Learn More about James C. Clemmer's net worth.

How old is James C. Clemmer?

Mr. Clemmer is currently 60 years old. There are 7 older executives and no younger executives at AngioDynamics. Learn More on James C. Clemmer's age.

What is James C. Clemmer's salary?

As the CEO of AngioDynamics, Inc., Mr. Clemmer earns $982,920.00 per year. Learn More on James C. Clemmer's salary.

How do I contact James C. Clemmer?

The corporate mailing address for Mr. Clemmer and other AngioDynamics executives is 14 PLAZA DRIVE, LATHAM NY, 12110. AngioDynamics can also be reached via phone at (518) 795-1400 and via email at [email protected]. Learn More on James C. Clemmer's contact information.

Has James C. Clemmer been buying or selling shares of AngioDynamics?

James C. Clemmer has not been actively trading shares of AngioDynamics within the last three months. Most recently, on Monday, October 10th, James C. Clemmer bought 10,000 shares of AngioDynamics stock. The stock was acquired at an average cost of $15.00 per share, with a total value of $150,000.00. Following the completion of the transaction, the chief executive officer now directly owns 450,407 shares of the company's stock, valued at $6,756,105. Learn More on James C. Clemmer's trading history.

Who are AngioDynamics' active insiders?

AngioDynamics' insider roster includes Chad Campbell (SVP), Scott Centea (VP), James Clemmer (CEO), James Clemmer (CEO), Dave Helsel (SVP), and Stephen Trowbridge (CFO). Learn More on AngioDynamics' active insiders.

James C. Clemmer Insider Trading History at AngioDynamics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/10/2022Buy10,000$15.00$150,000.00450,407View SEC Filing Icon  
1/11/2022Buy10,000$22.84$228,400.00View SEC Filing Icon  
7/31/2020Buy40,000$8.26$330,400.00343,319View SEC Filing Icon  
10/25/2019Buy15,000$14.19$212,850.00260,418View SEC Filing Icon  
7/21/2017Buy5,000$15.79$78,950.0086,683View SEC Filing Icon  
7/20/2017Buy20,000$15.64$312,800.0086,683View SEC Filing Icon  
See Full Table

James C. Clemmer Buying and Selling Activity at AngioDynamics

This chart shows James C Clemmer's buying and selling at AngioDynamics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AngioDynamics Company Overview

AngioDynamics logo
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
Read More

Today's Range

Now: $5.87
Low: $5.73
High: $5.90

50 Day Range

MA: $5.81
Low: $5.27
High: $6.22

2 Week Range

Now: $5.87
Low: $5.26
High: $12.62

Volume

428,799 shs

Average Volume

508,687 shs

Market Capitalization

$233.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66